BRAF and melanoma: Additionally, in mouse melanoma models, BRAF inhibitors reduced the number of regulatory T cells and MDSCs, with a simultaneous increase in the activity of antigen-presenting DCs, while anti-MEK therapy decreased the mortality of overstimulated effector T lymphocytes [41,42,43].